TheStreet.com |
Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer
TheStreet.com Tesaro (TSRO) won U.S. approval Monday for its PARP inhibitor niraparib as a new maintenance treatment for ovarian cancer patients responsive to platinum-based chemotherapy. The new Tesaro drug, to be marketed under the brand name Zejula, was ... FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers Tesaro stock rises 6% on news that its ovarian cancer drug was approved by the FDA FDA approves Tesaro's ovarian cancer drug |
from Health - Google News http://ift.tt/2mJNvwD
EmoticonEmoticon